Boron clusters (ferrabisdicarbollides) shaping the future as radiosensitizers for multimodal (chemo/radio/PBFR) therapy of glioblastoma
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Nuez Martínez, Miquel; Queralt-Martín, María; Aguilella, Vicente; VV.AA.
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/2507
comunitat-uji-handle3:10234/6973
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Boron clusters (ferrabisdicarbollides) shaping the future as radiosensitizers for multimodal (chemo/radio/PBFR) therapy of glioblastomaFecha de publicación
2022-10-24Editor
Royal Society of ChemistryISSN
2050-750X; 2050-7518Cita bibliográfica
Nuez-Martínez, M., Queralt-Martín, M., Muñoz-Juan, A., Aguilella, V. M., Laromaine, A., Teixidor, F., ... & Marques, F. (2022). Boron clusters (ferrabisdicarbollides) shaping the future as radiosensitizers for multimodal (chemo/radio/PBFR) therapy of glioblastoma. Journal of Materials Chemistry B, 10(47), 9794-9815.Tipo de documento
info:eu-repo/semantics/articleVersión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, and is highly resistant to conventional radiotherapy and chemotherapy. Therefore, the development of multidrug resistance and tumor ... [+]
Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, and is highly resistant to conventional radiotherapy and chemotherapy. Therefore, the development of multidrug resistance and tumor recurrence are frequent. Given the poor survival with the current treatments, new therapeutic strategies are urgently needed. Radiotherapy (RT) is a common cancer treatment modality for GBM. However, there is still a need to improve RT efficiency, while reducing the severe side effects. Radiosensitizers can enhance the killing effect on tumor cells with less side effects on healthy tissues. Herein, we present our pioneering study on the highly stable and amphiphilic metallacarboranes, ferrabis(dicarbollides) ([o-FESAN]− and [8,8′-I2-o-FESAN]−), as potential radiosensitizers for GBM radiotherapy. We propose radiation methodologies that utilize secondary radiation emissions from iodine and iron, using ferrabis(dicarbollides) as iodine/iron donors, aiming to achieve a greater therapeutic effect than that of a conventional radiotherapy. As a proof-of-concept, we show that using 2D and 3D models of U87 cells, the cellular viability and survival were reduced using this treatment approach. We also tested for the first time the proton boron fusion reaction (PBFR) with ferrabis(dicarbollides), taking advantage of their high boron (11B) content. The results from the cellular damage response obtained suggest that proton boron fusion radiation therapy, when combined with boron-rich compounds, is a promising modality to fight against resistant tumors. Although these results are encouraging, more developments are needed to further explore ferrabis(dicarbollides) as radiosensitizers towards a positive impact on the therapeutic strategies for GBM. [-]
Publicado en
J. Mater. Chem. B, 2022,10, 9794-9815Datos relacionados
https://www.rsc.org/suppdata/d2/tb/d2tb01818g/d2tb01818g1.pdfEntidad financiadora
Ministerio de Economía, Industria y Competitividad | Generalitat Valenciana | Fundação para a Ciência e a Tecnologia | Centro de Ciências e Tecnologias Nucleares | Research Unit on Applied Molecular Biosciences | Associate Laboratory Institute for Health and Bioeconomy | Ministerio de Ciencia, Innovación y Universidades | Universitat Jaume I | Croatian Science Foundation
Código del proyecto o subvención
PID2019-106832RB-100 | 2017SGR1720 | UID/Multi/04349/2019 | LISBOA-01-0247-FEDER-045904 | UTAP-EXPL/FMT/0020/2021 | PTDC/BTM-TEC/29256/2017 | UIDP/04565/2020 of iBB/IST | UIDP/04378/2020 | UIDB/04378/2020 | LA/P/0140/2020 | MCIN/AEI/10.13039/501100011033 | 2019-108434GB-I00 to VMA | IJC2018-035283-I to MQM | UJI-B2018-53 | UJI-A2020-21 | IP-2018-01-3168 | 689 DFA/BD/07119/2020
Derechos de acceso
This journal is © The Royal Society of Chemistry 2022
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- FCA_Articles [503]